RARE DISEASERESEARCH ATLAS

ORPHA:445038

3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome

low confidenceDisorder

Also known as: 3-methylglutaconic aciduria type 7 · MGA-neonatal cataract-neurologic involvement-congenital neutropenia syndrome · MGA7

Publications

4,795

Trials

0

Interventional, condition-specific

Researchers

226

Distinct authors in sample

Gene link

CLPB

Definitive

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare organic aciduria characterized by increased urinary excretion of 3-methylglutaconic acid, variably associated with neutropenia (sometimes causing recurrent severe infections and potentially resulting in leukemia) and neurologic manifestations, such as global , , , movement disorder, and . Microcephaly, cataract, facial dysmorphism, growth retardation, endocrine abnormalities, and have also been reported. Brain imaging may show cerebral or cerebellar atrophy, or abnormalities of the basal ganglia.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (5)

3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia · 3-methylglutaconic aciduria-cataract-neurologic involvement-neutropenia syndrome · CLPB 3-methylglutaconic aciduria · MEGCANN · MGCA7

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — CLPB

  2. LiteraturePresent

    4,795 matched papers (2,791 in last 10 years) Source

  3. Phenotype characterisedPresent

    90 HPO annotations (e.g. Nephrocalcinosis; Cerebellar atrophy; Myoclonus) Source

  4. Animal modelNot found

    No Alliance genotype “model of” associations via Monarch for these Mondo IDs

  5. Orphan designationNot found

    No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (CLPB).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

90

Associated phenotypes · MONDO:0014561

  • Nephrocalcinosis
  • Cerebellar atrophy
  • Myoclonus
  • Hyperreflexia
  • Growth delay

Showing 5 of 90 — open Monarch for the full list.

Animal models (Monarch / Alliance)

None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.

Open Targets candidates

No drugs or clinical candidates returned for this Mondo ID on Open Targets.

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

4,795

4,795 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

4,795 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

2,791 in the last 10 years · low confidence

Phrase hits: 28 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

226

Distinct author names in 28 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Shorter J5 papers · 2022

    Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

    Papers in Europe PMC
  2. 02
    Cupo RR4 papers · 2022

    Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA.

    Papers in Europe PMC
  3. 03
    Tzoneva G3 papers · 2024

    Regeneron Genetics Center, Tarrytown, NY, USA

    Papers in Europe PMC
  4. 04
    Braun GA2 papers · 2022

    Chemistry and Chemical Biology Graduate Program, Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA.

    Papers in Europe PMC
  5. 05
    Chuang E2 papers · 2022

    Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA; Pharmacology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.

    Papers in Europe PMC
  6. 06
    Greenway SC2 papers · 2022

    Departments of Pediatrics, Cardiac Sciences and Biochemistry & Molecular Biology, Cumming School of Medicine, Alberta Children's Hospital Research Institute and Libin Cardiovascular Institute, University of Calgary, Calgary, AB T2N 4N1, Canada.

    Papers in Europe PMC
  7. 07
    Halachev M2 papers · 2024

    MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, United Kingdom

    Papers in Europe PMC
  8. 08
    Khan A2 papers · 2022

    Departments of Pediatrics and Medical Genetics, Cumming School of Medicine, Alberta Children's Hospital Research Institute, University of Calgary, Calgary, AB T3B 6A8, Canada.

    Papers in Europe PMC
  9. 09
    Liu Y2 papers · 2022

    Department of Pediatrics, Dr. von Hauner Children's Hospital and Gene Center, University Hospital, Ludwig-Maximilians-Universität (LMU), Munich, Germany.

    Papers in Europe PMC
  10. 10
    Meynert A2 papers · 2024

    MRC Human Genetics Unit, Institute of Genetics and Cancer, University of Edinburgh, United Kingdom

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 11 September 2026 · last trial check 11 September 2026

No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.

low confidence · 38.6th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

Broader category 3-methylglutaconic aciduria also has no matched interventional trial. See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Broader category: 3-methylglutaconic aciduria

0

Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.

Parent-category matching found a broader label but no interventional trials under it. How we count trials.

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

Likely covered — the policy lists Organic acidemia as a category (Group 1), and this condition is a form of it. Confirm eligibility with a Centre of Excellence.

Group 1 — one-time curative treatment

Up to ₹50 lakh per patient

Financial support for treatment at notified Centres of Excellence (figures evolved from the original ₹20 lakh Group-1 ceiling).

Policy figures change. Verify current MoHFW / CoE guidance before relying on any amount. Verify

Centres of Excellence (15)
  • All India Institute of Medical Sciences (AIIMS)New Delhi, Delhi
  • Maulana Azad Medical CollegeNew Delhi, Delhi
  • Sanjay Gandhi Post Graduate Institute of Medical SciencesLucknow, Uttar Pradesh
  • Post Graduate Institute of Medical Education and Research (PGIMER)Chandigarh, Chandigarh
  • Centre for DNA Fingerprinting & Diagnostics with Nizam’s Institute of Medical SciencesHyderabad, Telangana
  • King Edward Memorial HospitalMumbai, Maharashtra
  • Institute of Post-Graduate Medical Education and Research (IPGMER)Kolkata, West Bengal
  • Centre for Human Genetics with Indira Gandhi HospitalBengaluru, Karnataka
  • Institute of Child Health and Hospital for Children (ICH & HC)Chennai, Tamil Nadu
  • All India Institute of Medical Sciences (AIIMS)Jodhpur, Rajasthan
  • Sree Avittam Thirunal Hospital (SAT), Government Medical CollegeThiruvananthapuram, Kerala
  • All India Institute of Medical Sciences (AIIMS)Bhopal, Madhya Pradesh
  • Regional Institute of Medical Sciences (RIMS)Imphal, Manipur
  • All India Institute of Medical Sciences (AIIMS)Patna, Bihar
  • Assam Medical College & HospitalDibrugarh, Assam

Voluntary contributions / crowdfunding (separate from CoE funding): https://rarediseases.mohfw.gov.in/

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome" OR "3-methylglutaconic aciduria type 7" OR "MGA-neonatal cataract-neurologic involvement-congenital neutropenia syndrome" OR "3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia" OR "3-methylglutaconic aciduria-cataract-neurologic involvement-neutropenia syndrome" OR "CLPB 3-methylglutaconic aciduria" OR "MEGCANN" OR "MGCA7") OR ("CLPB" OR "CLPB syndrome" OR "CLPB-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome" OR "3-methylglutaconic aciduria type 7" OR "MGA-neonatal cataract-neurologic involvement-congenital neutropenia syndrome" OR "3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia" OR "3-methylglutaconic aciduria-cataract-neurologic involvement-neutropenia syndrome" OR "CLPB 3-methylglutaconic aciduria" OR "MEGCANN" OR "MGCA7"

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Parent-category trials query:

"3-methylglutaconic aciduria"

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: MGA7

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (4795) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-27T16:30:17.492Z